Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ADCY3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ADCY3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADCY2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ADCY2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADCY1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ADCY1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADA 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ADA, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Pimavanserin tartrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pimavanserin tartrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Suvorexant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Suvorexant is a Small molecule drug targeting OX1R x OX2R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Spesolimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Spesolimab is a Monoclonal antibody targeting IL-36R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ritlecitinib Tosilate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ritlecitinib Tosilate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Abrocitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Abrocitinib is a Small molecule drug targeting JAK1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Upadacitinib hemihydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Upadacitinib hemihydrate is a Small molecule drug targeting JAK1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Dupilumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Dupilumab is a Monoclonal antibody targeting IL-4Rα, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Tisagenlecleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Tisagenlecleucel is a Autologous CAR-T targeting CD19, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.